-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On February 24, the traditional Chinese medicine sector strengthened
.
As of 10:32, Xinguang Pharmaceutical's increase was close to 15%, Foci Pharmaceutical's daily limit, in addition, Guangshengtang, Teyi Pharmaceutical, Zuoli Pharmaceutical, Taiji Group, Weikang Pharmaceutical, etc.
followed suit
.
Among them, Foci Pharmaceuticals has reached the daily limit twice in the past year
.
The company's main business is the research and development, manufacturing and sales of Chinese patent medicines and big health products, as well as the cultivation, processing and sales of Chinese herbal medicines
.
The main products include Liuwei Dihuang Pills, Xiaoyao Pills, Xiangsha Yangwei Pills, Ginseng Guben Huanshao Pills and other series of proprietary Chinese medicines, as well as Ejiao, Ejiao cakes and other large health products
.
In addition, the anti-epidemic materials produced by the company are medical surgical masks, N95 masks and 75% ethanol disinfectant, which are currently mainly sold in the market
.
Xintian Pharmaceutical has received 3 daily limit prices in a row this year.
The company is mainly engaged in the R&D and production of proprietary Chinese medicines.
Its business scope includes hard capsules, granules, tablets, mixtures, syrups, wine, dew, and powder
.
At present, the company has 52 varieties of 6 dosage forms, and the products are mainly Chinese patent medicine preparations
.
Looking at the traditional Chinese medicine industry, the rise of the sector since 2021 is closely related to policy support
.
Including "Several Policies and Measures on Accelerating the Development of Traditional Chinese Medicine Characteristics", "Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Traditional Chinese and Western Medicine", "Implementation Plan for the Dissemination of Traditional Chinese Medicine Culture (2021-2025)" and a series of other The favorable release boosted the confidence and determination of the industry to develop
.
Entering 2022, although the market of the traditional Chinese medicine sector has been adjusted, it has recently risen again
.
Regarding the future trend of the traditional Chinese medicine industry, analysts at Southwest Securities said that they are optimistic about traditional Chinese medicine consumer goods.
This segment has consumption attributes, mainly in the out-of-hospital market, and is relatively immune to medical insurance
.
Xiangcai Securities pointed out in a research report that since 2022, the Chinese herbal medicine market has shown an upward trend as a whole
.
The traditional Chinese medicine industry is supported by policies and has obvious advantages in low valuation.
It is recommended to pay attention to the targets with excellent performance in the annual report
.
The agency believes that for the traditional Chinese medicine industry, factors such as the demand side, the rigid demand characteristics of the pharmaceutical industry and the upgrading of pharmaceutical consumption jointly support the steady growth of demand in the traditional Chinese medicine industry
.
On the policy side, a series of favorable policies have been formed to promote the innovation of traditional Chinese medicine, develop formula granules, support medical insurance and payment policies, and continue to add no more than 25% of traditional Chinese medicine pieces, bringing policy dividends and new demand to the traditional Chinese medicine industry
.
The unique advantage of "preventive treatment of diseases" brings development opportunities to the Chinese medicine industry
.
On the performance side, the traditional Chinese medicine industry has come out of a low point, showing a marginal improvement trend
.
On the valuation side, the traditional Chinese medicine industry still has a relatively obvious valuation advantage
.
Based on "policy + pharmaceutical consumption upgrade + performance improvement + valuation advantage", there are investment opportunities in the traditional Chinese medicine industry, and the agency recommends focusing on policy encouragement areas and policy safe haven areas
.
In addition, the annual report season is approaching, it is recommended to pay attention to the targets with good annual report performance
.
As of February 24, a number of proprietary Chinese medicine companies have released their 2021 performance reports, including Pien Tze Huang, Shou Xian Gu, Ji Chuan Pharmaceutical, etc.
, and the overall performance is good
.
Among them, Pien Tze Huang's operating income in 2021 will achieve 8.
026 billion yuan, a year-on-year increase of 23.
27%; the net profit attributable to the parent is 2.
433 billion yuan, a year-on-year increase of 45.
55%; Shouxiangu's annual operating income is 767 million yuan, a year-on-year increase of 20.
61%; total profit 200 million yuan, a year-on-year increase of 30.
29%; Jichuan Pharmaceutical achieved operating income of 7.
6305 billion yuan in 2021, a year-on-year increase of 23.
77%; net profit attributable to shareholders of listed companies was 1.
664 billion yuan, an increase of 30.
31% compared with the same period last year
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
As of 10:32, Xinguang Pharmaceutical's increase was close to 15%, Foci Pharmaceutical's daily limit, in addition, Guangshengtang, Teyi Pharmaceutical, Zuoli Pharmaceutical, Taiji Group, Weikang Pharmaceutical, etc.
followed suit
.
Among them, Foci Pharmaceuticals has reached the daily limit twice in the past year
.
The company's main business is the research and development, manufacturing and sales of Chinese patent medicines and big health products, as well as the cultivation, processing and sales of Chinese herbal medicines
.
The main products include Liuwei Dihuang Pills, Xiaoyao Pills, Xiangsha Yangwei Pills, Ginseng Guben Huanshao Pills and other series of proprietary Chinese medicines, as well as Ejiao, Ejiao cakes and other large health products
.
In addition, the anti-epidemic materials produced by the company are medical surgical masks, N95 masks and 75% ethanol disinfectant, which are currently mainly sold in the market
.
Xintian Pharmaceutical has received 3 daily limit prices in a row this year.
The company is mainly engaged in the R&D and production of proprietary Chinese medicines.
Its business scope includes hard capsules, granules, tablets, mixtures, syrups, wine, dew, and powder
.
At present, the company has 52 varieties of 6 dosage forms, and the products are mainly Chinese patent medicine preparations
.
Looking at the traditional Chinese medicine industry, the rise of the sector since 2021 is closely related to policy support
.
Including "Several Policies and Measures on Accelerating the Development of Traditional Chinese Medicine Characteristics", "Opinions on Further Strengthening the Work of Traditional Chinese Medicine in General Hospitals to Promote the Coordinated Development of Traditional Chinese and Western Medicine", "Implementation Plan for the Dissemination of Traditional Chinese Medicine Culture (2021-2025)" and a series of other The favorable release boosted the confidence and determination of the industry to develop
.
Entering 2022, although the market of the traditional Chinese medicine sector has been adjusted, it has recently risen again
.
Regarding the future trend of the traditional Chinese medicine industry, analysts at Southwest Securities said that they are optimistic about traditional Chinese medicine consumer goods.
This segment has consumption attributes, mainly in the out-of-hospital market, and is relatively immune to medical insurance
.
Xiangcai Securities pointed out in a research report that since 2022, the Chinese herbal medicine market has shown an upward trend as a whole
.
The traditional Chinese medicine industry is supported by policies and has obvious advantages in low valuation.
It is recommended to pay attention to the targets with excellent performance in the annual report
.
The agency believes that for the traditional Chinese medicine industry, factors such as the demand side, the rigid demand characteristics of the pharmaceutical industry and the upgrading of pharmaceutical consumption jointly support the steady growth of demand in the traditional Chinese medicine industry
.
On the policy side, a series of favorable policies have been formed to promote the innovation of traditional Chinese medicine, develop formula granules, support medical insurance and payment policies, and continue to add no more than 25% of traditional Chinese medicine pieces, bringing policy dividends and new demand to the traditional Chinese medicine industry
.
The unique advantage of "preventive treatment of diseases" brings development opportunities to the Chinese medicine industry
.
On the performance side, the traditional Chinese medicine industry has come out of a low point, showing a marginal improvement trend
.
On the valuation side, the traditional Chinese medicine industry still has a relatively obvious valuation advantage
.
Based on "policy + pharmaceutical consumption upgrade + performance improvement + valuation advantage", there are investment opportunities in the traditional Chinese medicine industry, and the agency recommends focusing on policy encouragement areas and policy safe haven areas
.
In addition, the annual report season is approaching, it is recommended to pay attention to the targets with good annual report performance
.
As of February 24, a number of proprietary Chinese medicine companies have released their 2021 performance reports, including Pien Tze Huang, Shou Xian Gu, Ji Chuan Pharmaceutical, etc.
, and the overall performance is good
.
Among them, Pien Tze Huang's operating income in 2021 will achieve 8.
026 billion yuan, a year-on-year increase of 23.
27%; the net profit attributable to the parent is 2.
433 billion yuan, a year-on-year increase of 45.
55%; Shouxiangu's annual operating income is 767 million yuan, a year-on-year increase of 20.
61%; total profit 200 million yuan, a year-on-year increase of 30.
29%; Jichuan Pharmaceutical achieved operating income of 7.
6305 billion yuan in 2021, a year-on-year increase of 23.
77%; net profit attributable to shareholders of listed companies was 1.
664 billion yuan, an increase of 30.
31% compared with the same period last year
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
